OakChart

Akebia Therapeutics Inc

AKBAHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 11 • 12:01 PM ET

0.5184-0.0234 (-4.32%)
2026-11-11 18:02 CET
Market cap
150.44 USD m
Revenue, TTM
197.20 USD m
Net income, TTM
-44.56 USD m
Free cash flow, TTM
13.86 USD m
EPS diluted, TTM
-0.16
P/E
-
Compare

Price

AKBA against its 20, 50 and 200-day averages
2050200beatmiss
0.501.001.502.0011.5M22.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AKBAclose 0.5220-day 0.6250-day 0.79200-day 1.110.5252w high52w low

72.6% under the 52-week high of 1.89 on 12 Nov 2025. 52-week low 0.36 on 6 Nov 2026. Last 15 sessions, 121.6% high to low

Profile

AKBA
52-week range, 10% of the way up
0.361.89

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice Jr., Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

IndexRUT
Employees194
IPOMar 20, 2014
Beta0.26
ATR, 14d0.08
Rel volume0.36
Short float10.07%
Insider own2.71%
Inst own41.28%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap143.94M
Enterprise Value201.00M
Income-44.56M
Sales197.20M
Book/sh0.07
Cash/sh0.57
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees194
IPOMar 20, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S0.73
P/B7.06
P/C0.90
P/FCF10.39
EV/EBITDA-
EV/Sales1.02
Quick Ratio1.24
Current Ratio1.36
Debt/Eq10.62
LT Debt/Eq7.71
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.16
EPS next Y-0.34
EPS next Q-0.06
EPS this Y-758.33%
EPS next Y-99.03%
EPS next 5Y-
EPS past 3/5Y65.70% 62.40%
Sales past 3/5Y-6.88% -4.37%
EPS Y/Y TTM-118.99%
Sales Y/Y TTM-12.38%
EPS Q/Q-2690.00%
Sales Q/Q-37.20%
EarningsNov 05 BMO
EPS/Sales Surpr.-38.89% -21.38%

Ownership

Insider Own2.71%
Insider Trans-0.74%
Inst Own41.28%
Inst Trans2.49%
ROA-12.62%
ROE-143.83%
ROIC-25.12%
Gross Margin78.22%
Oper. Margin-14.07%
Profit Margin-22.60%
SMA20-16.68%
SMA50-34.38%
SMA200-53.46%
Trades-

Technical

Shs Outstand277.52M
Shs Float270.13M
Short Float10.07%
Short Ratio3.34
Short Interest27.20M
52W High1.89 -72.57%
52W Low0.36 43.52%
Volatility23.02% 12.55%
ATR (14)0.08
RSI (14)38.14
Beta0.26
Rel Volume0.36
Avg Volume8.14M
Volume1,231,505

Performance

Perf Week-25.38%
Perf Month-32.68%
Perf Quarter-40.39%
Perf Half Y-56.07%
Perf YTD-67.80%
Perf Year-71.36%
Perf 3Y-41.95%
Perf 5Y-82.43%
Perf 10Y-94.09%
Recom1.33
Target Price3.25
Prev Close0.54
Price0.52
Change %-4.32%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 07, 2026DowngradeLLeerink PartnersOutperform → Market Perform$1+92.9%
Jun 04, 2025ResumedHH.C. WainwrightBuy$8+1,443.2%
Apr 28, 2025InitiatedLLeerink PartnersOutperform$7+1,250.3%
Apr 01, 2025InitiatedJJefferiesBuy$6+1,057.4%
Nov 29, 2023ResumedBBTIG ResearchBuy$4+671.6%
Aug 28, 2023UpgradeHH.C. WainwrightNeutral → Buy$3.75+623.4%
May 31, 2023UpgradePPiper SandlerNeutral → Overweight$2 → $4+671.6%
Mar 31, 2022DowngradePPiper SandlerOverweight → Neutral$8 → $2+285.8%
Mar 31, 2022DowngradeNNeedhamBuy → Hold
Mar 31, 2022DowngradeMMizuhoBuy → Neutral$6 → $2+285.8%

Peers

Mkt cap
TickerCompanyMkt cap
ARDXArdelyx Inc779.25M
UNCYUnicycive Therapeutics Inc103.62M
RMTIRockwell Medical Inc28.41M
AMGNAMGEN Inc249.76B
GSKGSK Plc ADR100.37B
OPKOpko Health Inc1.22B
PROKProKidney Corp345.15M
TVTXTravere Therapeutics Inc4.94B
VERAVera Therapeutics Inc2.18B
DVADaVita Inc11.28B

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Butler John P.CEO and PresidentAug 06 '26Option Exercise0.63350,000220,5003,718,564Aug 10 04:08 PM
Ostrowski ErikSVP, CFO, CBO & TreasurerJun 29 '26Sale1.1156,01962,181616,616Jul 01 04:34 PM
Ostrowski ErikOfficerJun 29 '26Proposed Sale1.1156,01962,220Jun 29 08:38 PM
Butler John P.CEO and PresidentMar 04 '26Buy1.2569,27086,5883,367,064Mar 05 06:55 PM
Malabre Richard CSVP, Chief Accounting OfficerFeb 02 '26Sale1.3949,52468,838299,390Feb 04 04:15 PM
Grund NicholasChief Commercial OfficerFeb 02 '26Sale1.3984,829117,912561,750Feb 04 04:13 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 02 '26Sale1.3967,65894,045948,432Feb 04 04:13 PM
Rucci Carolyn M.SVP, Chief Legal OfficerFeb 02 '26Sale1.3969,77296,983588,378Feb 04 04:12 PM
Ostrowski ErikSVP, CFO, CBO & TreasurerFeb 02 '26Sale1.3934,95148,582672,635Feb 04 04:11 PM
Butler John P.CEO and PresidentFeb 02 '26Sale1.39341,305474,4143,206,233Feb 04 04:10 PM
Ostrowski ErikOfficerFeb 02 '26Proposed Sale1.3934,95148,739Feb 02 05:58 PM
Grund NicholasOfficerFeb 02 '26Proposed Sale1.3984,829118,294Feb 02 05:57 PM
Burke Steven KeithOfficerFeb 02 '26Proposed Sale1.3967,65894,349Feb 02 05:55 PM
Butler John P.OfficerFeb 02 '26Proposed Sale1.39341,305475,950Feb 02 05:54 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
SMLFiShares U.S. Small-Cap Equity Factor ETFAUM: 4.26B

News

latest 14 of 206
  • Akebia Misses As Vafseo Destocking And A Sharply Lower Post-TDAPA Price Overshadow Its Best Clinical Evidence Yet (Earnings Whispers) -38.75%
  • Akebia Therapeutics: Q3 Earnings Snapshot (Associated Press)
  • Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
  • Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin (GlobeNewswire)
  • Akebia's Vafseo Ramp Faces Its First Post-VOICE Test As Auryxia Erosion Drags The Top Line (Earnings Whispers)
  • Loading…
  • Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
  • U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week (GlobeNewswire) +13.57%
  • Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum (GlobeNewswire)
  • Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 (GlobeNewswire)
  • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.33%
  • Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases (GlobeNewswire)
  • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.050-0.036-0.05036.9046.946
2026Q22026-08-05-0.030-0.042-0.03349.1348.855
2026Q12026-05-07-0.030-0.028-0.03453.5451.675
2025Q42026-02-26-0.050-0.036-0.04657.6246.095
2025Q32025-11-100.000-0.0110.00258.7758.235
2025Q22025-08-070.000-0.0150.00162.4747.245
2025Q12025-05-080.030-0.0380.02557.3444.535
2024Q42025-03-13-0.100-0.081-0.10446.5037.343
2024Q32024-11-07-0.100-0.063-0.09537.4344.503
2024Q22024-08-08-0.040-0.072-0.04143.6049.802
2024Q12024-05-09-0.090-0.072-0.08832.6146.093
2023Q42024-03-140.000-0.0380.00356.2055.393
2023Q32023-11-08-0.080-0.085-0.07742.0048.182
2023Q22023-08-25-0.060-0.025-0.06056.3859.102
2023Q12023-05-08-0.140-0.145-0.14240.1346.682
2022Q42023-03-09-0.040-0.183-0.05055.1847.403

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.360-2.073-2.362335358.54
2020FY-2.770-2.539-2.769295.31288.48
2021FY-1.700-1.637-1.699213.58205.76
2022FY-0.510-0.640-0.516292.6284.82
2023FY-0.280-0.308-0.277194.62193.88
2024FY-0.330-0.306-0.329160.18151.04
2025FY-0.0200.003-0.020236.2229.24
2026FY--0.172--180.09
2027FY--0.342--107.54
2028FY--0.238--128.59
2029FY--0.172--149.63
2030FY--0.060--199.97

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0560436.9526.8051.30
2026Q4S2026-10-2860048.1740.8058.50
2026Q4S2026-10-2060148.1740.8058.50
2026Q4S2026-09-0461348.1740.8058.50
2026Q4S2026-08-1451347.5440.8058.50
2026Q4S2026-08-0651250.8040.8061.88
2026Q4S2026-07-2850054.5037.6061.88
2026Q4S2026-07-2150154.5037.6061.88
2026Q4S2026-05-1450554.5037.6061.88
2026Q4S2026-05-1250459.5837.6083.40
2026Q4S2026-05-0750559.5837.6083.40
2026Q4S2026-04-2450562.9740.3083.40
2026Q4S2026-04-2351468.1540.3087.60
2026Q4S2026-02-2652368.4940.3087.60

Estimate history

EPS, annual-1.694-2.474-2.362-2.769-1.699-0.516-0.277-0.329-0.021-0.1649
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.095-0.1040.0250.0010.002-0.046-0.034-0.033-0.052
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual181.227207.742335.001295.307211.65292.484194.623160.18236.196197.2
Period201720182019202020212022202320242025TTM
Sales, quarterly37.42846.49757.33662.47258.76657.62253.54449.12836.903
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual47.613116.888121.675148.074177.001184.136194.583224.849265.425277.516
Period201720182019202020212022202320242025MRQ
Shares, quarterly211.542224.849261.645263.042265.226265.425267.898271.743277.516
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue197.20236.20160.18194.62292.48211.65295.31335.00207.74
Cost of Goods Sold Incl. D&A42.9540.7368.8475.7387.22152.60182.46145.358.67
Gross Profit154.25195.4791.34118.89205.2659.05112.85189.65199.07
Selling, General and Administrative Excl. Other182.00171.97141.76164.96270.11323.55373.77475.94354.14
Research and Development70.3661.0931.9961.49128.33145.93216.41322.97291.01
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-27.7523.50-50.41-46.08-64.85-264.50-260.92-286.29-155.06
Interest Expense15.7324.1818.186.0315.6919.948.871.40-
Unusual Expense-0.433.100.911.4717.90-0.60115.81-23.10
Net Income Before Taxes-43.18-3.72-69.41-51.92-94.23-282.02-383.46-286.29-171.93
Income Taxes1.381.620.000.000.000.000.00-6.63-28.34
Consolidated Net Income-44.56-5.34-69.41-51.92-94.23-282.02-383.46-279.66-143.59
Net Income From Continuing Operations-44.56-5.34-69.41-51.92-94.23-282.02-383.46-279.66-143.59
Net Income-44.56-5.34-69.41-51.92-94.23-282.02-383.46-279.66-143.59
EPS (Recurring)-0.16-0.01-0.33-0.27-0.45-1.70-2.18-2.36-2.20
EPS (Basic, Before Extraordinaries)-0.16-0.02-0.33-0.28-0.52-1.70-2.77-2.36-2.47
EPS (Diluted)-0.16-0.02-0.33-0.28-0.52-1.70-2.77-2.36-2.47
EBITDA-26.4124.77-8.71-4.23-29.57-228.37-227.32-249.87-152.65
Non-Operating Income (Expense)-0.130.060.091.654.211.812.141.406.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.198.917.789.3214.6522.7324.468.7115.04
Price To Sales Ratio1.291.752.501.190.361.771.312.231.54
Gross Margin78.2282.7657.0361.0970.1827.9038.2156.6195.83
Operating Margin-14.079.95-31.47-23.67-22.17-124.97-88.35-85.46-74.64
Net Margin-22.60-2.26-43.33-26.68-32.22-133.25-129.85-83.48-69.12
Shares Outstanding277.52265.42224.85194.58184.14177.00148.07121.67116.89
Market Capitalization150.44150.44414.54233.60106.15395.41404.71751.72641.48

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue36.9049.1353.5457.6258.7762.4757.3446.50
Cost of Goods Sold Incl. D&A6.4611.0112.6212.869.7010.237.9424.90
Gross Profit30.4438.1240.9344.7749.0652.2449.4021.60
Selling, General and Administrative Excl. Other40.5642.5045.6253.3244.6238.1535.8835.91
Research and Development16.0813.4714.4826.3314.6310.709.447.25
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.12-4.38-4.70-8.554.4514.0913.51-14.31
Interest Expense3.143.074.694.834.756.837.776.88
Unusual Expense0.911.38-0.46-2.26-1.466.98-0.151.68
Net Income Before Taxes-14.18-8.84-8.93-11.231.160.256.11-22.80
Income Taxes0.170.070.131.010.610.000.000.00
Consolidated Net Income-14.35-8.91-9.05-12.240.540.256.11-22.80
Net Income From Continuing Operations-14.35-8.91-9.05-12.240.540.256.11-22.80
Net Income-14.35-8.91-9.05-12.240.540.256.11-22.80
EPS (Recurring)-0.05-0.03-0.04-0.05-0.000.020.02-0.10
EPS (Basic, Before Extraordinaries)-0.05-0.03-0.03-0.050.000.000.03-0.10
EPS (Diluted)-0.05-0.03-0.03-0.050.000.000.03-0.10
EBITDA-10.02-3.80-4.37-8.234.7714.4013.83-0.76
Non-Operating Income (Expense)-0.01-0.010.00-0.12-0.01-0.030.210.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.212.552.902.532.542.682.191.70
Price To Sales Ratio1.291.401.601.813.334.842.512.59
Gross Margin82.4977.5976.4377.6983.4983.6286.1546.45
Operating Margin-27.42-8.92-8.77-14.847.5722.5523.57-30.77
Net Margin-38.90-18.13-16.91-21.250.920.4010.66-49.04
Shares Outstanding277.52271.74267.90265.42265.23263.04261.64224.85
Market Capitalization150.44305.81372.35427.24723.85956.00501.56414.54

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments186.5451.8742.9290.47149.80269.08147.96321.64317.79
Short Term Receivables47.0334.3739.2941.0655.8928.5738.8616.6734.22
Inventories15.6116.2415.6921.5736.6361.02116.35114.250.00
Other Current Assets3.7711.3520.2432.0828.8312.766.3615.726.35
Total Current Assets252.96113.83118.15185.18271.15371.44309.53468.27358.36
Net Property, Plant & Equipment4.8810.4216.0534.3740.6135.5039.428.023.62
Total Investments and Advances0.001.681.652.702.042.042.092.461.28
Intangible Assets59.0459.0495.09131.13167.17199.22346.26383.210.00
Deferred Tax Assets-------112.780.18
Other Assets59.6835.7010.772.6748.3835.9473.89134.580.99
Total Assets376.56220.67241.70356.05529.35644.14771.201,109.32364.43
Short Term Debt Incl. Current Port. of LT Debt40.0815.6424.0436.74102.345.294.9915.000.00
Accounts Payable21.1815.1814.6318.0233.5941.3139.2242.807.00
Income Tax Payable-------0.000.99
Other Current Liabilities101.6750.1061.2074.77125.12140.55163.91207.90133.12
Total Current Liabilities162.9480.9199.87129.54261.05187.15208.12265.69141.11
Long Term Debt176.21179.0280.14120.5286.78121.00103.330.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-------119.410.18
Other Liabilities4.809.9392.27100.77107.5188.3864.9988.29100.57
Total Liabilities343.95269.86272.29350.82455.34396.52376.44473.39241.85
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity32.61-49.19-30.585.2374.01247.62394.76635.93122.57
Total Shareholders Equity32.61-49.19-30.585.2374.01247.62394.76635.93122.57
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity32.61-49.19-30.585.2374.01247.62394.76635.93122.57
Total Liabilities & Stockholders Equity376.56220.67241.70356.05529.35644.14771.201,109.32364.43
Book Value Per Share0.12-0.22-0.160.030.421.673.245.442.57
Tangible Book Value Per Share-0.10-0.48-0.65-0.68-0.530.330.402.162.57
Full-Time Employees194181167205426379360325114
Price to Book Ratio7.38-7.97-5.927.665.231.671.951.027.03
Return on Assets-1.79-30.02-17.37-21.38-48.07-54.19-29.74-19.49-22.17
Return on Equity----230.70-175.37-119.39-54.27-38.02-77.27
Return on Invested Capital-2.56-53.46-104.77-74.93-175.40-104.03-56.15-22.58-60.10
Quick Ratio1.461.211.031.260.901.660.931.332.54
Current Ratio1.551.411.181.431.041.981.491.762.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-44.56-5.34-69.41-51.92-94.23-282.02-383.46-279.66-143.59
Depreciation1.331.2741.7041.8535.2836.1333.5936.422.42
Other Funds (Non Cash)48.6255.6026.737.42-12.7798.54253.1591.5035.99
Funds from Operations5.4051.52-0.98-2.66-71.71-147.35-96.72-158.37-133.51
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital10.3816.47-39.68-20.73-1.44-105.61-13.67-99.0736.02
Cash from Operating Activities15.7867.99-40.66-23.38-73.15-252.97-110.39-257.44-97.49
Capital Expenditures-1.92-0.29-0.030.00-0.11-0.06-0.32-6.66-1.61
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.170.000.000.000.000.000.006.15
Purchase or Sale of Investments0.000.000.000.000.0040.00-39.69217.8332.05
Purchase of Investments0.000.000.000.000.000.00-99.930.00-224.22
Sale Or Maturity of Investments0.000.000.000.000.0040.0060.24217.83256.27
Other Uses-12.71-7.810.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-14.62-7.93-0.030.00-0.1139.94-40.00211.1836.59
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock10.4468.3643.036.797.6088.95211.7526.7396.58
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.4468.3643.036.797.6088.95211.7526.7396.58
Proceedsfrom Stock Options11.4968.1342.886.717.1288.20209.4225.7995.45
Issuance or Reduction of Debt, Net-19.584.636.63-32.00-33.0044.7819.9862.67-0.02
Change in Long Term Debt-19.584.636.63-32.00-33.0044.7819.9862.67-0.02
Issuance of Long Term Debt0.0010.0045.000.000.0044.7819.9877.670.00
Reduction of Long Term Debt-19.58-5.37-38.37-32.00-33.000.000.00-15.00-0.02
Net Financing Active Other Cash Flow0.00-0.060.000.0040.000.000.00-0.430.00
Other Financing Activities Uses0.00-0.060.000.000.000.000.00-0.430.00
Cash from Financing Activities-9.1472.9349.66-25.2114.60133.73231.7288.9796.56
Net Change in Cash-7.98132.998.97-48.59-58.67-79.2981.3342.7035.66
Free Cash Flow13.8667.70-40.69-23.38-73.27-253.02-110.70-264.10-99.10
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow18.376.12-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00-6.63-28.34

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments159.25157.26164.35186.54168.14137.31
Short Term Receivables36.4453.5162.5447.0366.2272.81
Inventories18.7013.0213.0015.6118.6416.71
Other Current Assets6.395.773.603.775.337.83
Total Current Assets220.78229.55243.48252.96258.34234.66
Net Property, Plant & Equipment12.087.313.424.886.317.70
Total Investments and Advances0.900.000.000.000.001.69
Intangible Assets59.0459.0459.0459.0459.0459.04
Other Assets49.3253.7556.5759.6840.4642.50
Total Assets342.13349.66362.52376.56364.15345.60
Short Term Debt Incl. Current Port. of LT Debt59.3349.5659.8740.0834.3632.46
Accounts Payable7.619.428.3921.1810.0911.55
Other Current Liabilities95.41101.89105.63101.6788.9474.71
Total Current Liabilities162.35160.87173.88162.94133.38118.72
Long Term Debt156.99161.25158.06176.21178.94178.10
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.422.523.214.8010.2419.55
Total Liabilities321.76324.64335.14343.95322.56316.37
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity20.3725.0227.3832.6141.5929.22
Total Shareholders Equity20.3725.0227.3832.6141.5929.22
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity20.3725.0227.3832.6141.5929.22
Total Liabilities & Stockholders Equity342.13349.66362.52376.56364.15345.60
Book Value Per Share0.070.090.100.120.160.11
Tangible Book Value Per Share-0.14-0.13-0.12-0.10-0.07-0.11
Full-Time Employees---194--
Price to Book Ratio7.3811.1611.3110.2724.5738.74
Return on Assets-12.62-8.53-6.10-1.79-5.57-12.90
Return on Equity-143.83-109.38-78.96---
Return on Invested Capital-8.09-4.78-4.88-5.860.240.12
Quick Ratio1.241.351.331.461.801.84
Current Ratio1.361.431.401.551.941.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-14.35-8.91-9.05-12.240.540.25
Depreciation0.100.580.330.320.320.32
Other Funds (Non Cash)7.308.0812.0621.188.0216.68
Funds from Operations-6.95-0.243.339.268.8817.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital9.283.77-24.5421.8719.235.10
Cash from Operating Activities2.333.52-21.2131.1328.1122.34
Capital Expenditures-0.71-1.08-0.06-0.07-0.08-0.13
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses-1.90-3.000.00-7.810.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.61-4.08-0.06-7.88-0.08-0.13
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock6.903.330.150.061.111.72
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.903.330.150.061.111.72
Proceedsfrom Stock Options6.573.240.001.680.001.54
Issuance or Reduction of Debt, Net-3.73-9.86-1.08-4.910.000.00
Change in Long Term Debt-3.73-9.86-1.08-4.910.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-3.73-9.86-1.08-4.910.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.18-6.54-0.93-4.851.111.72
Net Change in Cash2.90-7.09-22.2018.4029.1423.94
Free Cash Flow1.632.45-21.2731.0628.0322.22
Price to Free Cash Flow18.377.636.186.3123.28-

Revenue breakdown

License Collaboration And Other2024: 8.00M 2025: 8.86M
Product2024: 152.18M 2025: 227.33M
United States2024: 160.18M 2025: 236.20M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.07%27.2M270.1M7.75M
2026-10-158.56%23.1M269.6M6.58M
2026-09-308.34%22.5M269.6M6.05M
2026-09-157.61%20.5M269.6M6.16M
2026-08-318.54%23.0M269.3M5.80M
2026-08-147.94%21.4M269.3M5.20M
2026-07-317.08%19.2M271.1M4.97M
2026-07-157.32%19.1M260.8M5.06M
2026-06-307.35%19.2M260.8M4.61M
2026-06-1511.19%29.2M261.0M3.92M
2026-05-2910.51%27.4M261.0M3.51M
2026-05-1510.19%26.4M258.9M3.05M
2026-04-3010.67%27.6M258.9M2.98M
2026-04-1510.57%27.3M258.5M3.02M
2026-03-3110.16%26.3M258.5M3.23M
2026-03-1311.21%29.0M258.5M3.23M
2026-02-2711.49%29.7M258.5M3.30M
2026-02-1312.19%31.2M256.1M3.51M
2026-01-3014.59%36.9M253.1M3.73M
2026-01-1514.42%37.0M256.8M4.23M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.100.082.82067.008.000.613-0.0040.000
call1.000.000.050.054.6001920.000.294-0.0070.000
call1.500.000.050.025.5431000.000.252-0.0080.000
call2.000.001.000.006.8390.000.000.237-0.0100.000
call3.000.000.050.027.4681.000.000.215-0.0100.000
call4.000.001.000.008.7080.000.000.210-0.0110.000
put0.500.000.050.056.89412.000.00-0.312-0.0090.000
put1.000.150.900.4518.8020.000.00-0.706-0.0070.000
put1.500.601.350.0017.2020.000.00-0.745-0.0090.000
put2.001.101.851.2518.0531.000.00-0.763-0.0090.000
put3.002.002.900.0021.9150.000.00-0.780-0.0100.000
put4.003.004.000.000.0000.000.00-0.790-0.0110.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-238-KCurrent report2026-10-21SEC
2026-10-148-KCurrent report2026-10-07SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-308-KCurrent report2026-06-30SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-228-KCurrent report2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-05-12SCHEDULE 13GSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-28SEC
2026-04-15PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-15SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-033Initial statement of beneficial ownership of securities2026-04-01SEC
2026-04-018-KCurrent report2026-03-27SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-054Statement of changes in beneficial ownership of securities2026-03-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060062.18K1
2026-050000
2026-040000
2026-0386.59K100
2026-0200900.77K6
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.7.45%
VANGUARD CAPITAL MANAGEMENT LLC4.22%
AQR CAPITAL MANAGEMENT LLC3.41%
ACADIAN ASSET MANAGEMENT LLC3.24%
GEODE CAPITAL MANAGEMENT, LLC2.29%
STATE STREET CORP2.01%
JACOBS LEVY EQUITY MANAGEMENT, INC1.59%
Nantahala Capital Management, LLC1.49%
GOLDMAN SACHS GROUP INC1.38%
MILLENNIUM MANAGEMENT LLC1.19%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.95%
iShares Russell 2000 ETF2.53%
VANGUARD EXTENDED MARKET INDEX FUND1.18%
Fidelity Small Cap Index Fund1.05%
iShares Russell 2000 Growth ETF0.81%
Fidelity Enhanced Small Cap Core ETF0.61%
VANGUARD RUSSELL 2000 INDEX FUND0.53%
Schwab U.S. Small-Cap ETF0.45%
iShares Micro-Cap ETF0.32%
VANGUARD HEALTH CARE INDEX FUND0.28%

OakChart. AKBA. Cached 15 minutes.